CA2654371A1 - Therapeutic compounds - Google Patents

Therapeutic compounds Download PDF

Info

Publication number
CA2654371A1
CA2654371A1 CA002654371A CA2654371A CA2654371A1 CA 2654371 A1 CA2654371 A1 CA 2654371A1 CA 002654371 A CA002654371 A CA 002654371A CA 2654371 A CA2654371 A CA 2654371A CA 2654371 A1 CA2654371 A1 CA 2654371A1
Authority
CA
Canada
Prior art keywords
pain
adenosine
amino
purin
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002654371A
Other languages
English (en)
French (fr)
Inventor
Edward Daniel Savory
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2654371A1 publication Critical patent/CA2654371A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002654371A 2006-06-27 2007-06-26 Therapeutic compounds Abandoned CA2654371A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0601397-3 2006-06-27
SE0601397 2006-06-27
US83740206P 2006-08-11 2006-08-11
US60/837,402 2006-08-11
PCT/EP2007/056377 WO2008000744A2 (en) 2006-06-27 2007-06-26 2-0'-methyladen0sine derivatives and their use as agonists or antagonists of an adenosine receptor

Publications (1)

Publication Number Publication Date
CA2654371A1 true CA2654371A1 (en) 2008-01-03

Family

ID=38573394

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002654371A Abandoned CA2654371A1 (en) 2006-06-27 2007-06-26 Therapeutic compounds

Country Status (10)

Country Link
US (1) US7820811B2 (enExample)
EP (1) EP2081932A2 (enExample)
JP (1) JP2009541437A (enExample)
CN (1) CN101479268B (enExample)
AU (1) AU2007263727A1 (enExample)
BR (1) BRPI0713902A2 (enExample)
CA (1) CA2654371A1 (enExample)
NZ (1) NZ573307A (enExample)
RU (1) RU2009102536A (enExample)
WO (1) WO2008000744A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ573308A (en) * 2006-06-27 2012-02-24 Biovitrum Ab Publ Adenosine derivatives for the treatment of pain
WO2012048013A2 (en) * 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843066A (en) 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1991006556A1 (en) * 1989-10-24 1991-05-16 Gilead Sciences, Inc. 2' modified oligonucleotides
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
US5705491A (en) 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
ES2194320T3 (es) 1997-06-03 2003-11-16 Itochu Techno Chem Inc Sustancias naturales antivirales o antitumorales y uso de las mismas.
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
KR20050055630A (ko) 2002-06-28 2005-06-13 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료를 위한 1'-, 2'- 및 3'-변형된뉴클레오시드 유도체
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0328323D0 (en) 2003-12-05 2004-01-07 Cambridge Biotechnology Ltd Synthesis of 2-substituted adenosines
KR20070004792A (ko) 2004-03-05 2007-01-09 캠브리지 바이오테크놀로지 리미티드 아데노신 수용체 작용제
NZ573308A (en) 2006-06-27 2012-02-24 Biovitrum Ab Publ Adenosine derivatives for the treatment of pain

Also Published As

Publication number Publication date
RU2009102536A (ru) 2010-08-10
AU2007263727A1 (en) 2008-01-03
BRPI0713902A2 (pt) 2012-11-27
WO2008000744A3 (en) 2008-02-28
US20080009461A1 (en) 2008-01-10
WO2008000744A2 (en) 2008-01-03
CN101479268B (zh) 2012-08-08
EP2081932A2 (en) 2009-07-29
NZ573307A (en) 2012-02-24
JP2009541437A (ja) 2009-11-26
US7820811B2 (en) 2010-10-26
CN101479268A (zh) 2009-07-08

Similar Documents

Publication Publication Date Title
KR102020004B1 (ko) 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
CA2557285A1 (en) Adenosine receptor agonists
AU746590B2 (en) Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US7906518B2 (en) Therapeutic compounds
KR20190113864A (ko) C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
EP2081946B1 (en) Adenosine derivatives for the treatment of pain
US7820811B2 (en) Pro-drugs of adenosine receptor agonists
KR20240145467A (ko) dsRNA, 이의 응용 및 제조 방법
JP2008505967A (ja) Ａ１アデノシンレセプターアゴニストの製造方法
CN104447923A (zh) 2’-脱氧-2’-氟-2’-甲基核苷衍生物及其制备方法与在制药中的用途
KR102025415B1 (ko) C형 간염 바이러스 억제 화합물, 약학 조성물 및 그 응용
HK1129109A (en) 2-0'-methyladenosine derivatives and their use as agonists or antagonists of an adenosine receptor
HK1129117A (en) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
US5426101A (en) 2-substituted adenosines with A-2 receptor affinity
HK1129228A (en) Therapeutic compounds
JP2012102114A (ja) アデノシン受容体アゴニスト

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130626